The next chapter for group B meningococcal vaccines

The next chapter for group B meningococcal vaccines

The majority of invasive meningococcal disease (IMD) in the developed world is caused by capsular group B Neisseria meningitidis, however success with vaccination against organisms bearing this capsule has previously been restricted to control of geographically limited clonal outbreaks. As we enter...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Wang, N, Pollard, A
Format:	Journal article
Język:	English
Wydane:	Taylor and Francis 2017

Podobne zapisy

Group B meningococcal vaccine science and policy
od: Drysdale, SB, i wsp.
Wydane: (2015)

Group B meningococcal vaccine: Recommendations for UK use
od: Pollard, A, i wsp.
Wydane: (2014)

Group B meningococcal vaccine: recommendations for UK use.
od: Pollard, A, i wsp.
Wydane: (2014)

Four component meningococcal capsular Group B vaccine in preterm infants.
od: Sadarangani, M, i wsp.
Wydane: (2017)

Meningococcal vaccines.
od: Rüggeberg, J, i wsp.
Wydane: (2004)

Meningococcal vaccines.
od: Collins, C, i wsp.
Wydane: (2002)

Meningococcal vaccines.
od: Bethell, D, i wsp.
Wydane: (2002)

Serogroup B meningococcal vaccines-an unfinished story.
od: Sadarangani, M, i wsp.
Wydane: (2010)

The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.
od: Rollier, C, i wsp.
Wydane: (2014)

Quadrivalent meningococcal conjugate vaccines
od: Pace, D, i wsp.
Wydane: (2009)

Quadrivalent meningococcal conjugate vaccines.
od: Pace, D, i wsp.
Wydane: (2009)

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
od: Rivero-Calle I, i wsp.
Wydane: (2019-10-01)

Vaccines for prevention of meningococcal disease.
od: Pollard, A, i wsp.
Wydane: (2000)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
od: Dold, C, i wsp.
Wydane: (2023)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
od: Lewis, S, i wsp.
Wydane: (2009)

Gonococcal Vaccine Development: Lessons from Group B Meningococcal Vaccines
Wydane: (2017-08-01)

Meningococcal meningitis presenting postinfant group B meningococcal immunisation
od: So, N, i wsp.
Wydane: (2018)

Safety of meningococcal group B vaccination in hospitalised premature infants
od: Kent, A, i wsp.
Wydane: (2018)

The epidemiology of meningococcal disease and the impact of vaccines.
od: Khatami, A, i wsp.
Wydane: (2010)

Meningococcal disease and vaccination in North America.
od: Pollard, A, i wsp.
Wydane: (2001)

Reconsideration of the use of meningococcal polysaccharide vaccine.
od: Granoff, D, i wsp.
Wydane: (2007)

Meningococcal polysaccharide-protein conjugate vaccines.
od: Snape, MD, i wsp.
Wydane: (2005)

Impact of meningococcal group B OMV vaccines, beyond their brief
od: Helen Petousis-Harris
Wydane: (2018-05-01)

Development of group B meningococcal vaccine: a progress review
od: Wei ZHAO, i wsp.
Wydane: (2022-08-01)

Global epidemiology of meningococcal disease and vaccine efficacy
od: Pollard, A
Wydane: (2004)

Global epidemiology of meningococcal disease and vaccine efficacy.
od: Pollard, A
Wydane: (2004)

Emerging clinical experience with vaccines against group B meningococcal disease
od: Wilkins, A, i wsp.
Wydane: (2017)

Vaccine prevention of meningococcal disease, coming soon?
od: Morley, S, i wsp.
Wydane: (2001)

Vaccine prevention of meningococcal disease, coming soon?
od: Morley, S, i wsp.
Wydane: (2001)

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
od: Sadarangani, M, i wsp.
Wydane: (2017)

Enter B and W: two new meningococcal vaccine programmes launched.
od: Ladhani, S, i wsp.
Wydane: (2016)

Enter B and W: two new meningococcal vaccine programmes launched
od: Ladhani, S, i wsp.
Wydane: (2015)

Correlation of group C meningococcal conjugate vaccine response with B- and T-lymphocyte activity.
od: James B Wing, i wsp.
Wydane: (2012-01-01)

Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine
od: Weissmueller, N, i wsp.
Wydane: (2017)

Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps
od: F. Marc LaForce, i wsp.
Wydane: (2018-05-01)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
od: O'Connor, D, i wsp.
Wydane: (2020)

Meningococcal disease
od: Pollard, A
Wydane: (2018)

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine
od: Daniel O’Connor, i wsp.
Wydane: (2020-11-01)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
od: Read, R, i wsp.
Wydane: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
od: Read, R, i wsp.
Wydane: (2014)